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Mechanisms that cause Alzheimer’s disease (AD), an invariably fatal neurodegenerative disease, are unknown. Important recent
data indicate that neuronal heme deficiency may contribute to AD pathogenesis. If true, factors that contribute to the intracellular
heme deficiency could potentially alter the course of AD. The porphyrias are metabolic disorders characterized by enzyme defi-
ciencies in the heme biosynthetic pathway. We hypothesize that AD may differ significantly in individuals possessing the genetic
trait for an acute hepatic porphyria. We elaborate on this hypothesis and briefly review the characteristics of the acute hepatic por-
phyrias that may be relevant to AD.We note the proximity of genes encoding enzymes of the heme biosynthesis pathway to genetic
loci linked to sporadic, late-onset AD. In addition, we suggest that identification of individuals carrying the genetic trait for acute
porphyria may provide a unique resource for investigating AD pathogenesis and inform treatment and management decisions.
Copyright © 2006 Barney E. Dwyer et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
AD is a progressive and invariably fatal neurodegenerative
disease and the leading cause of senile dementia [1]. Synaptic
and neuronal loss best correlates with cognitive decline [2].
Metabolic imbalance in diseased neurons may contribute to
neuropsychiatric symptoms that include delusions and hal-
lucinations, anxiety, mood disorder, and sleep disturbance
that are common in AD [3]. Mechanisms that cause AD are
unknown. Recently we proposed a hypothesis that explains
why elevated plasma homocysteine is a risk factor for AD
[4, 5]. Implicit in that hypothesis is development of neu-
ronal heme deficiency, and evidence of heme deficiency in
AD brains has been reported [6]. Here, we extend this theme
by considering the possible impact of porphyria on AD. The
porphyrias are metabolic disorders characterized by enzyme
deficiencies in the heme biosynthesis pathway. We propose
that an understanding of porphyria may provide novel in-
sights into AD pathogenesis.
GENERAL CONSIDERATIONS
Molecular and biochemical aspects of the porphyrias and
their diagnosis and treatment are the subject of several excel-
lent reviews [7–13]. Eight enzymes are required for de novo
heme biosynthesis. With the exception of 5-aminolevulinic
acid synthase [ALAS, EC 2.3.1.37], the initial and rate-lim-
iting enzyme of the heme biosynthesis pathway, deficiency
in one of the other seven enzymes is associated with a spe-
cific form of inherited porphyria [10]. Four of the hepatic
porphyrias, so-called because liver is the major site of ex-
pression of the enzymatic defect in heme biosynthesis, are
designated “acute” porphyrias because clinical expression
of the disease is associated with an acute neurologic syn-
drome (the acute attack or porphyric crisis) [8, 11]. These
are the extremely rare Doss porphyria (deficiency of ALA de-
hydratase, EC 4.2.1.24), acute intermittent porphyria (defi-
ciency of porphobilinogen deaminase, EC 4.3.1.8), heredi-
tary coproporphyria (deficiency of coproporphyrinogen ox-
idase, EC 1.3.3.3), and variegate porphyria (deficiency of
protoporphyrinogen oxidase, EC 1.3.3.4). Acute intermittent
porphyria is generally the most common form of acute hep-
atic porphyria encountered. Significantly, enzyme deficien-
cies are present in other organs, including the brain, and the
enzyme deficiency is life-long.
Acute neurologic syndrome associated with clinical at-
tacks of acute hepatic porphyria can include both neuropsy-
chiatric symptoms and neurodegenerative change [8, 11, 12].
Neuropsychiatric symptoms that include anxiety, insomnia,
confusion, hallucinations, agitation, and paranoia (so-called
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porphyric encephalopathy-8) underscore CNS involvement.
Autonomic neuropathy may underlie severe abdominal pain
and cardiovascular symptoms. In severe cases, a periph-
eral neuropathy resembling Guillain-Barre syndrome can de-
velop [8, 11]. Clinical attacks of acute porphyria can be in-
duced in latent individuals by a variety of environmental fac-
tors including many common medications, nutritional fac-
tors, restricted carbohydrate and calorie intake, smoking,
and hormones such as progesterone; lists of safe and un-
safe drugs are available [9, 11, 12]. A common mechanism
of inducing agents is believed to be greatly increased hep-
atic heme demand. Thus, biosynthesis of cytochrome P450
enzymes that utilize heme as a prosthetic group can be in-
duced as much as 40–50-fold in liver by drugs such as bar-
biturates [11]. Increased heme demand results in the induc-
tion of ALAS and increased synthesis of the heme precur-
sor, 5-aminolevulinic acid [ALA]. In individuals who have
inherited a partial deficiency in one of the enzymes of the
heme biosynthesis pathway, that enzyme and not ALAS is the
rate-limiting step in heme biosynthesis. Then, ALA and other
heme precursors can accumulate. Moreover, heme biosyn-
thesis is insufficient to meet demand and heme deficiency is
unresolved. Acute attacks are treated with infusions of glu-
cose and hemin [9, 12]. Hemin restores the regulatory heme
pool. This suppresses hepatic ALAS induction and the over-
production of ALA and other heme precursors. Glucose infu-
sion may also suppress ALAS but by a different mechanism.
Fasting, which can induce the acute attack, appears to acti-
vate transcriptional coactivator PGC-1α (via a cAMP/CREB
pathway) and PGC-1α greatly increases hepatic ALAS expres-
sion by activating transcription factors NRF-1 and FOXO1
[14, 15]. In addition, ALAS may respond directly to cAMP
[14, 15]. Glucose appears to antagonize both pathways. Ab-
dominal pain and psychotic symptoms resolve quickly upon
timely treatment of the acute attack but peripheral neuropa-
thy can require months to resolve and recovery is often in-
complete [11].
The pathogenesis of nervous system dysfunction in the
acute attack remains unclear. There are two predominant hy-
potheses [8, 11]. One suggests functional heme deficiency de-
velops during the acute attack, in liver and possibly in neu-
ral tissues, and impairs critical cell processes dependent on
hemoproteins such as energy production by the mitochon-
drial electron transport chain. Studies utilizing mice defi-
cient in porphobilinogen deaminase, an experimental model
of acute intermittent porphyria, underscore the importance
of functional heme deficiency in nervous tissue in the devel-
opment of motor neuropathy [16–18]. The second hypothe-
sis suggests that heme precursors and their metabolites accu-
mulate to toxic levels during the acute attack. ALA, in partic-
ular, is implicated because it is produced excessively in all the
acute hepatic porphyrias and may have neurotoxic proper-
ties [8, 11]. Excessive ALA production occurs in lead poison-
ing due to lead-mediated inhibition of ALA dehydratase, and
also in hereditary infantile tyrosinemia (type I) in which the
enzyme defect leads to endogenous production of the ALA
dehydratase inhibitor, succinylacetone [19]. In both diseases,
neuropsychiatric symptoms that resemble those of the acute
attack occur [8, 11]. While recent clinical studies underscore
the potential importance of excessive hepatic production of
heme precursors as the primary cause of the neurologic com-
plications in the acute porphyric attack [20, 21], induced ele-
vation of plasma ALA in a human volunteer, by itself, did not
produce symptoms of porphyria [22]. Clearly, many details
are unresolved [8, 11].
DOES PORPHYRIA OFFER INSIGHT ON AD?
We hypothesize that heme deficiency is important in AD
pathogenesis and that AD may differ significantly in indi-
viduals possessing the genetic trait for an acute hepatic por-
phyria because there is the potential to develop more severe
heme deficiency. Figure 1 schematically depicts this hypoth-
esis.
AD-related factors may create an imbalance in neuronal
heme supply and demand. In AD, heme supply may be re-
duced. Aging is the greatest risk factor for development of
AD, and at least in rat brain, heme biosynthesis declines
in normal aging [25]. Nutritional factors could be impor-
tant. Pyridoxine deficiency in the aged could contribute to
age-related decrease in heme biosynthesis because pyridoxal
phosphate is a cofactor for ALAS [10]. Glycoxidation reac-
tions are prominent in AD brain [26], and glycoxidation re-
actions might inactivate enzymes required for heme biosyn-
thesis [27]. Moreover, heme biosynthesis requires mitochon-
drial integrity and mitochondrial damage is prominent in
AD [28]. In AD, heme demand may be increased. Mito-
chondrial damage would necessitate increasedmitochondrial
turnover and de novo synthesis of heme-containing proteins
such as cytochromes. Moreover, mitochondrial damage may
itself be caused by heme deficiency [29, 30] thus creating a vi-
cious cycle further impairing heme biosynthesis. Glycoxida-
tion reactions could promote degradation of heme proteins
[31]. Heme degradation may be favored over heme biosyn-
thesis in AD neurons because of chronically elevated HO-1
[32, 33]. Factors unique to AD could also increase heme de-
mand. Thus, amyloid-β [Aβ] binds heme, which may con-
tribute to development of a functional heme deficiency [6]
and affect Aβ toxicity by inhibiting Aβ aggregation [34, 35].
We speculate that the reduced capacity to synthesize heme in
individuals with porphyria could exacerbate such an imbal-
ance in heme supply and demand.
In addition, the two proposed mechanisms of nervous
system dysfunction in the acute porphyric attack, functional
heme deficiency and toxic accumulation of ALA, have cellu-
lar effects that could be important in AD pathogenesis. Inhi-
bition of heme biosynthesis produced senescence-associated
changes in gene expression in cultured mouse cortical neu-
rons [36] and was proapoptotic in NGF-induced PC12 cells
[37]. Increased oxidative stress, which is one of the ear-
liest observed events in AD pathogenesis [38], and heme
deficiency may help explain several pathophysiological fea-
tures of AD including mitochondrial abnormalities and im-
paired energy metabolism, cell cycling and cell signaling
abnormalities, neuritic pathology, and abnormal expression
of iron regulatory protein 2 (IRP2) [5]. ALA is a source of
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Figure 1: AD and porphyria. Oxidative stress and free radical damage occur early in AD [23]. Disruption in iron homeostatic mechanisms
contributes to oxidative damage in AD [24]. A consequence of oxidative stress predicted by the ferric cycle hypothesis is heme deficiency
[4, 5]. Moreover, AD-related factors such as accumulation of amyloid-β may limit heme bioavailability [6]. We hypothesize that reduced
capacity for cells to synthesize heme, in individuals with the genetic trait for acute hepatic porphyria, contributes to development of heme
deficiency (and possibly oxidative stress). AD-related pathological change and neuropsychiatric and behavioral symptoms associated with
AD may be more severe in these individuals.
oxygen free radicals in the presence of heavy metals such as
iron [39]. The product of iron-catalyzed oxidation of ALA, 4,
5-dioxovaleric acid, is an effective alkylating agent of guanine
moieties in DNA in vitro [40, 41], and ALA-induced mito-
chondrial and nuclear DNA damage has been shown in sev-
eral cell lines including PC12 cells [42]. Moreover, ALA may
disrupt normal iron sequestration by ferritin. It released iron
from ferritin in vitro [43, 44] and caused oxidative damage
to the ferritin molecule [45]. As in the toxic mechanism pro-
posed for homocysteine in AD pathogenesis [4, 5], ALA may
make available a catalytic metal that can promote oxidative
stress.
DOES PORPHYRIA INCREASE THE RISK OF AD?
Clinically overt acute hepatic porphyria (predominantly
acute intermittent porphyria) is relatively rare with a preva-
lence of perhaps 5 per 100,000 [12]. However, the preva-
lence of the genetic trait for acute porphyria is far greater
because perhaps 90% of affected individuals are clinically la-
tent [7, 12]. In a Finnish population the estimated prevalence
of porphobilinogen deaminase deficiency, the biochemical
defect in acute intermittent porphyria, was 1 per 500 [46].
Using gene analysis to supplement enzymatic analysis, the
estimated prevalence of porphobilinogen deaminase defi-
ciency in a French population was 1 per 1675 [47]. Con-
sistent with the possibility that deficiency in heme biosyn-
thesis could increase susceptibility for AD is the intriguing
observation that the chromosomal location of genes encod-
ing enzymes in the heme biosynthesis pathway correlate with
genetic loci linked to sporadic, late-onset Alzheimer’s dis-
ease (maximum lod score  1) [48] (Table 1). However, the
significance of this observation is unclear. In cases such as
deficiency in porphobilinogen deaminase, heme deficiency
alone may be insufficient to cause AD but could contribute
to disease progression when superimposed on other disease
processes. However, effects may be indirect and not related
to heme levels. For example, the proximity of the ALA de-
hydratase gene to an AD-related locus is noted in Table 1.
ALA dehydratase-porphyria is an extremely rare form of
acute hepatic porphyria. Moreover, ALA dehydratase activ-
ity is far in excess of the activities of other enzymes in the
heme biosynthetic pathway and for that reason > 95% loss
of activity is needed before clinical symptoms of porphyria
develop [12]. However, ALA dehydratase is also a high Km
enzyme. Under AD-associated conditions, toxic levels of ALA
may possibly accumulate and contribute to AD pathogenesis.
While interesting, any relationship between heme deficiency
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Table 1: Chromosomal locations of genes encoding enzymes of the
heme biosynthesis pathway and genes linked to development of late-
onset Alzheimer’s disease.
Heme biosynthetic enzymes Location1
Closest
AD-related loci2
ALAS-1 (EC 2.3.1.37) 3p21 3p14, 3p26
ALA-dehydratase
9q34 9q34
(EC 4.2.1.24)3
Porphobilinogen
11q23.3 11q25
deaminase (EC 4.3.1.8)3
Uroporphyrinogen
10q25.3 10q21–10q25
III synthase (EC 4.2.1.75)
Uroporphyrinogen
1p34 1p31–1p36
decarboxylase (EC 4.1.1.37)
Coproporphyrinogen
3q12 3q28
III oxidase (EC 1.3.3.3)3
Protoporphyrinogen
1q22 1q23, 1q24
oxidase (EC 1.3.3.4)3
Ferrochelatase
18q21.3 18q22
(EC 4.99.1.1)
1 from Meissner et al [10].
2 From Table 1 by Kamboh in [48].
3 A deficiency is associated with a specific form of acute hepatic
porphyria.
and AD is speculative. If the genetic trait for one of the acute
hepatic porphyrias is a risk factor for AD, why has this rela-
tionship gone unnoticed? The answer simply may be that the
majority of individuals with the biochemical defects of acute
porphyria are clinically latent, and that many genetic and en-
vironmental factors likely contribute to the development of
sporadic, late-onset AD.
CONCLUSIONS
AD may differ significantly in individuals who have the ge-
netic trait for acute hepatic porphyria because there is the
potential to develop more severe neuronal heme deficiency
and possibly accumulate ALA and other heme precursors.
Epidemiological data confirming a link between AD and por-
phyria would be an important test of the hypothesis. AD pro-
gression (from disease-free state, to mild cognitive impair-
ment, to AD) in individuals with a genetic trait for acute
hepatic porphyria could be compared with AD progression
in an unaffected cohort. Testing for the presence of a genetic
trait for acute porphyria in individuals diagnosed with mild
cognitive impairment or early AD might identify a unique
subset of AD patients. Management decisions may need to
be adjusted in such individuals to avoid potential sensitivity
to commonmedications and novel therapeutic agents which,
if porphyrinogenic, could exacerbate porphyria and possibly
AD symptoms. Approaches such as these could yield signifi-
cant new information on AD pathogenesis and treatment.
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